Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(3.06)
# 528
Out of 5,218 analysts
37
Total ratings
56.25%
Success rate
48.50%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Eyenovia
Downgrades: Neutral
n/a
n/a n/a 1 Nov 18, 2024
United Therapeutics
Maintains: Strong Buy
319 344
361.37 -4.81% 7 Oct 31, 2024
UroGen Pharma
Maintains: Strong Buy
48 54
11.35 371.37% 1 Jun 14, 2024
TG Therapeutics
Maintains: Strong Buy
39 40
32.03 24.88% 3 May 2, 2024
Liquidia
Maintains: Strong Buy
15 30
10.91 174.98% 2 Dec 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
8 9
5.21 63.15% 4 Aug 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
122 173
n/a n/a 3 Jul 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 16
10.4 53.85% 1 May 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Mar 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
1071
3.3 32354.55% 2 Feb 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
17 23
0.47 4793.62% 1 Jun 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Apr 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Mar 21, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
450
n/a n/a 1 Nov 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Jan 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
51
5.09 901.96% 1 Dec 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
16
8.22 94.65% 1 Oct 14, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
45
5.73 685.34% 1 Jan 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Jan 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
40
n/a n/a 1 Feb 16, 2017